John Xue

5.4k total citations
13 papers, 417 citations indexed

About

John Xue is a scholar working on Molecular Biology, Cell Biology and Oncology. According to data from OpenAlex, John Xue has authored 13 papers receiving a total of 417 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 6 papers in Cell Biology and 5 papers in Oncology. Recurrent topics in John Xue's work include DNA Repair Mechanisms (6 papers), Microtubule and mitosis dynamics (5 papers) and Cancer therapeutics and mechanisms (4 papers). John Xue is often cited by papers focused on DNA Repair Mechanisms (6 papers), Microtubule and mitosis dynamics (5 papers) and Cancer therapeutics and mechanisms (4 papers). John Xue collaborates with scholars based in United States and South Africa. John Xue's co-authors include Zhan Xiao, Thomas J. Sowin, Haiying Zhang, Saul H. Rosenberg, Haichao Zhang, Zhi‐Fu Tao, Nan‐Horng Lin, Gaoquan Li, Wen‐Zhen Gu and Mai H. Bui and has published in prestigious journals such as Blood, Cancer Research and Oncogene.

In The Last Decade

John Xue

12 papers receiving 410 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John Xue United States 9 352 240 67 57 35 13 417
Luana D’Artista Italy 7 414 1.2× 228 0.9× 54 0.8× 76 1.3× 52 1.5× 9 496
Curtis H. Kugel United States 8 382 1.1× 239 1.0× 57 0.9× 48 0.8× 69 2.0× 8 461
Avital Lev United States 11 215 0.6× 182 0.8× 110 1.6× 51 0.9× 43 1.2× 20 386
Lucia García-Gutiérrez Spain 9 305 0.9× 132 0.6× 62 0.9× 68 1.2× 45 1.3× 15 417
Neele Drobnitzky United Kingdom 6 421 1.2× 168 0.7× 58 0.9× 56 1.0× 23 0.7× 6 497
Hélène Malka-Mahieu France 6 387 1.1× 136 0.6× 51 0.8× 29 0.5× 45 1.3× 10 456
Candice L. Horn United States 6 457 1.3× 251 1.0× 64 1.0× 81 1.4× 27 0.8× 10 552
Elizabeth Blackwood United States 10 351 1.0× 194 0.8× 55 0.8× 52 0.9× 38 1.1× 26 465
Jienan Kong China 9 293 0.8× 113 0.5× 62 0.9× 53 0.9× 25 0.7× 13 408
Silvia Licciulli Italy 8 366 1.0× 127 0.5× 83 1.2× 59 1.0× 45 1.3× 8 470

Countries citing papers authored by John Xue

Since Specialization
Citations

This map shows the geographic impact of John Xue's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Xue with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Xue more than expected).

Fields of papers citing papers by John Xue

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Xue. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Xue. The network helps show where John Xue may publish in the future.

Co-authorship network of co-authors of John Xue

This figure shows the co-authorship network connecting the top 25 collaborators of John Xue. A scholar is included among the top collaborators of John Xue based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Xue. John Xue is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Goddard, Wayne, et al.. (2022). Compelling colorings: A generalization of the dominator chromatic number. Applied Mathematics and Computation. 428. 127193–127193.
2.
Phillips, Darren C., Fritz G. Buchanan, Dong Cheng, et al.. (2021). Hexavalent TRAIL Fusion Protein Eftozanermin Alfa Optimally Clusters Apoptosis-Inducing TRAIL Receptors to Induce On-Target Antitumor Activity in Solid Tumors. Cancer Research. 81(12). 3402–3414. 32 indexed citations
3.
Tahir, Stephen K., Morey L. Smith, Larry R. Solomon, et al.. (2017). Abbv-621 Is a Novel and Potent TRAIL Receptor Agonist Fusion Protein That Induces Apoptosis Alone and in Combination with Navitoclax and Venetoclax in Hematological Tumors. Blood. 130. 2812–2812. 8 indexed citations
4.
Lam, Lloyd T., Haichao Zhang, John Xue, Joel Johansson, & Anahita Bhathena. (2015). Antihelminthic benzimidazoles potentiate navitoclax (ABT-263) activity by inducing Noxa-dependent apoptosis in non-small cell lung cancer (NSCLC) cell lines. Cancer Cell International. 15(1). 5–5. 11 indexed citations
5.
Zhang, Haichao, John Xue, Paul Hessler, et al.. (2015). Genomic analysis and selective small molecule inhibition identifies BCL-XL as a critical survival factor in a subset of colorectal cancer. Molecular Cancer. 14(1). 126–126. 43 indexed citations
6.
Chen, Jun, Sha Jin, Paul Tapang, et al.. (2014). CDK9 Inhibition Reverses Resistance to ABT-199 (GDC-0199) By Down-Regulating MCL-1. Blood. 124(21). 2161–2161. 1 indexed citations
7.
Lam, Lloyd T., Haichao Zhang, John Xue, et al.. (2014). Abstract 2759: Colorectal cancer cell lines with high BCL-XL and low MCL-1 expression are sensitive to a potent and selective BCL-XL inhibitor. Cancer Research. 74(19_Supplement). 2759–2759. 3 indexed citations
8.
Xiao, Zhan, John Xue, Wen‐Zhen Gu, et al.. (2008). Cyclin B1 is an efficacy-predicting biomarker for Chk1 inhibitors. Biomarkers. 13(6). 579–596. 20 indexed citations
9.
Hasvold, Lisa, Le Wang, Zhan Xiao, et al.. (2008). Investigation of novel 7,8-disubstituted-5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-ones as potent Chk1 inhibitors. Bioorganic & Medicinal Chemistry Letters. 18(7). 2311–2315. 10 indexed citations
10.
Chen, Zehan, Zhan Xiao, Wen‐Zhen Gu, et al.. (2006). Selective Chk1 inhibitors differentially sensitize p53‐deficient cancer cells to cancer therapeutics. International Journal of Cancer. 119(12). 2784–2794. 103 indexed citations
11.
12.
Xiao, Zhan, John Xue, Dimitri Semizarov, et al.. (2005). Novel indication for cancer therapy: Chk1 inhibition sensitizes tumor cells to antimitotics. International Journal of Cancer. 115(4). 528–538. 36 indexed citations
13.
Xiao, Zhan, John Xue, Thomas J. Sowin, Saul H. Rosenberg, & Haiying Zhang. (2004). A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation. Oncogene. 24(8). 1403–1411. 73 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Luana D’Artista Breakdown of academic impact, for papers by Curtis H. Kugel Breakdown of academic impact, for papers by Avital Lev Breakdown of academic impact, for papers by Lucia García-Gutiérrez Breakdown of academic impact, for papers by Neele Drobnitzky Breakdown of academic impact, for papers by Hélène Malka-Mahieu Breakdown of academic impact, for papers by Candice L. Horn Breakdown of academic impact, for papers by Elizabeth Blackwood Breakdown of academic impact, for papers by Jienan Kong Breakdown of academic impact, for papers by Silvia Licciulli
Rankless by CCL
2026